S‐adenosylmethionine and its metabolite induce apoptosis in HepG2 cells: Role of protein phosphatase 1 and Bcl‐xS

Heping Yang, Mamatha R. Sadda, Mei Li, Ying Zeng, Lixin Chen, Wanjun Bae, Xiaopeng Ou, Maria T. Runnegar, José M. Mato, Shelly C. Lu – 30 June 2004 – S‐adenosylmethionine (SAMe) and its metabolite 5′‐methylthioadenosine (MTA) are proapoptotic in HepG2 cells. In microarray studies, we found SAMe treatment induced Bcl‐x expression. Bcl‐x is alternatively spliced to produce two distinct mRNAs and proteins, Bcl‐xL and Bcl‐xS. Bcl‐xL is antiapoptotic, while Bcl‐xS is proapoptotic.

Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source

Susan M. McKiernan, Richard Hagan, Michael Curry, George S. A. McDonald, Alan Kelly, Niamh Nolan, Anne Walsh, John Hegarty, Emer Lawlor, Dermot Kelleher – 30 June 2004 – The role of cytotoxic T lymphocyte responses, restricted by human leukocyte antigen (HLA) class I alleles, is recognized as highly significant in the successful clearance of hepatitis C virus (HCV). The frequency of class I alleles in females inoculated with HCV genotype 1b from a single source was examined for an association with outcome.

Mitochondrial nitric oxide synthase drives redox signals for proliferation and quiescence in rat liver development

María C. Carreras, Daniela P. Converso, Alicia S. Lorenti, Mariana Barbich, Damián M. Levisman, Ariel Jaitovich, Valeria G. Antico Arciuch, Soledad Galli, Juan J. Poderoso – 30 June 2004 – Mitochondrial nitric oxide synthase (mtNOS) is a fine regulator of oxygen uptake and reactive oxygen species that eventually modulates the activity of regulatory proteins and cell cycle progression.

Characterization of mutations in ATP8B1 associated with hereditary cholestasis

Leo W. J. Klomp, Julie C. Vargas, Saskia W. C. van Mil, Ludmila Pawlikowska, Sandra S. Strautnieks, Michiel J. T. van Eijk, Jenneke A. Juijn, Carlos Pabón‐Peña, Lauren B. Smith, Joseph A. DeYoung, Jane A. Byrne, Justijn Gombert, Gerda van der Brugge, Ruud Berger, Irena Jankowska, Joanna Pawlowska, Erica Villa, A. S. Knisely, Richard J. Thompson, Nelson B. Freimer, Roderick H. J. Houwen, Laura N. Bull – 30 June 2004 – Progressive familial intrahepatic cholestasis (PFIC) and benign recurrent intrahepatic cholestasis (BRIC) are clinically distinct hereditary disorders.

The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope?

Michael Trauner – 30 June 2004 – Farnesoid X receptor (FXR) is a bile acid–activated transcription factor that is a member of the nuclear hormone receptor superfamily. FXR‐null mice exhibit a phenotype similar to Byler disease, an inherited cholestatic liver disorder. In the liver, activation of FXR induces transcription of transporter genes involved in promoting bile acid clearance and represses genes involved in bile acid biosynthesis.

Hypertonic preconditioning prevents hepatocellular injury following ischemia/reperfusion in mice: A role for interleukin 10

George D. Oreopoulos, Heshui Wu, Kati Szaszi, Jie Fan, John C. Marshall, Rachel G. Khadaroo, Ruijan He, Andras Kapus, Ori D. Rotstein – 30 June 2004 – Ischemia/reperfusion (I/R) of the liver occurs in many clinical scenarios including trauma, elective surgery, and transplantation. Events initiated by this process can lead to inflammation in the liver, culminating in local injury as well as distant organ dysfunction. Recent studies have suggested that hypertonic saline exerts anti‐inflammatory effects, which may be beneficial in preventing organ injury.

Effects of antiviral therapy on the cellular immune response in acute hepatitis C

Fareed Rahman, Theo Heller, Yuji Sobao, Eishiro Mizukoshi, Michelina Nascimbeni, Harvey Alter, Steven Herrine, Jay Hoofnagle, T. Jake Liang, Barbara Rehermann – 30 June 2004 – Spontaneous recovery occurs in a minority of patients with acute hepatitis C but is associated with vigorous and long‐lasting cellular immune responses. Treatment‐induced recovery can be achieved in the majority of patients who are treated in the acute phase, but the kinetics and mechanisms of viral clearance and immune responsiveness are not known.

Subscribe to